Substance Abuse in California: How Much Progress Has Been Made? Addiction of substances is very harmful. It needs a sober mind and high level of understanding to assist an addict to come out of the habit. Substances that are prone to abuse include alcohol and narcotics (heroin, cocaine, marijuana among others) It is a long […]
Investor News: Investigation of ProNAi Therapeutics Inc (NASDAQ:DNAI) over potential Violations of Securities Laws
An investigation for investors in NASDAQ:DNAI shares over potential securities laws violations by ProNAi Therapeutics and certain of its directors was announced. Investors who purchased shares of ProNAi Therapeutics Inc (NASDAQ:DNAI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554. The investigation by a law firm focuses […]
PCN’s housing first program helping to end chronic veteran homelessness in Phoenix
The People of Color Network (PCN) in cooperation with its community partners in mental health have announced a new program called the “Whole Health and Housing Project” aimed to help chronically homeless Veterans (and non veterans) who struggle with co-occurring substance abuse disorders get housing and treatment they need and deserve. This begins with housing first! […]
Multi-Center Pediatric Research Study Targets Cancer with T Cells
Researchers at the Children’s Hospital of Michigan, part of the Detroit Medical Center (DMC), the Wayne State University School of Medicine and the Barbara Ann Karmanos Cancer Institute in Detroit are partnering with Memorial Sloan Kettering Cancer Center in New York to offer patients a new investigational treatment option recently approved by the Food and […]
MolMed TK ASCO new data from the pivotal Phase III randomized trial TK008
MolMed S.p.A. (MLM.MI) provided at the 50th ASCO annual meeting new data from the ongoing randomised pivotal Phase III study on its cell therapy product TK for high-risk acute leukaemia patients transplanted from partially matched (haplo-identical) donors. The intent-to-treat analysis of the first 24 patients treated with TK indicates a 74% 1-year disease free survival […]
TK submission for Conditional Approval validated by EMA
MolMed S.p.A. (Milan:MLM) announces that the European Medicines Agency (EMA) has validated the submission of the Conditional Marketing Authorisation for TK, a novel proprietary investigational cell-gene therapy. The data review of the submitted dossier starts today. TK is an adjunctive treatment in hematopoietic stem cell transplantation for patients affected by high risk leukaemia. TK has […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 9
- Next Page »